04.01.11
PPD, Inc. has been selected as a preferred provider to a consortium of 14 global health Product Development Partners (PDPs) to develop medicines for some of the world’s poorest countries. PPD will provide discovery, clinical development and post-approval services for drug and vaccine development for health initiatives for infectious diseases like HIV, tuberculosis and malaria and neglected diseases such as visceral leishmaniasis, Chagas disease and Human African trypanosomiasis.
“PPD is committed to enhancing health care worldwide by delivering the safest, most reliable drug discovery and development services,” said David Grange, chief executive officer of PPD. “Our company has a long history of supporting global government and public health initiatives, and we are pleased to share our clinical research capabilities with consortium members to help get safe, effective medicines to those who need them.”
Megan Paye, vice president of government and public health services for PPD, added, “This initiative aligns with PPD’s extensive experience in neglected tropical diseases and supports our mission of expanding work with nonprofit organizations to improve global health. Having worked in infrastructure-constrained settings, PPD will bring unique site evaluation, capacity planning/site management, physician relationships, and multinational global regulatory and quality strategies to benefit the PDPs in advancing their drug development programs.”
“PPD is committed to enhancing health care worldwide by delivering the safest, most reliable drug discovery and development services,” said David Grange, chief executive officer of PPD. “Our company has a long history of supporting global government and public health initiatives, and we are pleased to share our clinical research capabilities with consortium members to help get safe, effective medicines to those who need them.”
Megan Paye, vice president of government and public health services for PPD, added, “This initiative aligns with PPD’s extensive experience in neglected tropical diseases and supports our mission of expanding work with nonprofit organizations to improve global health. Having worked in infrastructure-constrained settings, PPD will bring unique site evaluation, capacity planning/site management, physician relationships, and multinational global regulatory and quality strategies to benefit the PDPs in advancing their drug development programs.”